Studies On The Expression Of Muscarinic Receptors: Implications For The Pathology Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$498,791.00
Summary
Schizophrenia is a severe psychiatric disorder that affects approximately 1% of the population. This project will help define changes in the molecules in the brain of subjects with schizophrenia which are likely to be involved in two symptoms of the disorder, the psychoses and cognitive deficits. Understanding the cause of the cognitive deficits of schizophrenia is a high priority because they are the most disabilitating symptom of the disorder and do not respond to current drug treatments.
Antipsychotic Medication In First-episode Psychosis: An RCT To Assess The Risk-benefit Ratio
Funder
National Health and Medical Research Council
Funding Amount
$1,141,117.00
Summary
There has been an increasing emphasis on intervening early in psychotic disorders. A fundamental principle in early intervention is “to do no harm” and benefits must outweigh the risks of treatment. While antipsychotic medication is very effective and evidence-based form of treatment for positive symptoms in most first episode psychosis (FEP) patients it has risks. This study has the potential to determine whether antipsychotic medication should be the initial treatment option for FEP.
Predictors Of Outcome And Intervention In The ‘Ultra-High Risk’ For Psychosis Population
Funder
National Health and Medical Research Council
Funding Amount
$401,561.00
Summary
This area of research is concerned with improving our ability to identify young help-seeking patients who are most at risk of developing psychotic disorders and provide intervention to delay or prevent the onset of psychosis. A number of studies are planned, including researching disturbances in sense of self, neurocognitive factors, history of trauma and reaction to stress as predictive of future onset of psychosis, as well as a study of omega-3 fatty acids (fish oil) as an intervention for the ....This area of research is concerned with improving our ability to identify young help-seeking patients who are most at risk of developing psychotic disorders and provide intervention to delay or prevent the onset of psychosis. A number of studies are planned, including researching disturbances in sense of self, neurocognitive factors, history of trauma and reaction to stress as predictive of future onset of psychosis, as well as a study of omega-3 fatty acids (fish oil) as an intervention for these high risk young people.Read moreRead less
Does Antipsychotic Dose Reduction Lead To Better Functional Recovery In First Episode Psychosis: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,371,552.00
Summary
Can a person with a first episode of psychosis, once remitted, reduce their dosage of medication and still achieve better outcomes in functioning, physical health and brain volume, than if they had stayed on traditional maintenance doses of medication? This study will examine if using a dose reduction strategy in conjunction with an evidence based suite of psychosocial interventions leads to better social and vocational recovery and improved physical health and brain volume.
Rates Of Psychosis Onset In A High Risk Population
Funder
National Health and Medical Research Council
Funding Amount
$310,359.00
Summary
Older studies of people at risk of schizophrenia found that about 35% of them developed psychosis within 1 year. However the risk has decreased lately to as low as 10%. They may still become psychotic but take longer to do so, or they may not develop psychosis at all. We need to study this so that those not “at risk” are not needlessly treated. We will follow up “at risk” people and determine their 6 year outcome. We will do scans to see if there are any brain changes associated with psychosis.
Developmental Schizotypy In The General Population: Early Risk Factors And Predictive Utility.
Funder
National Health and Medical Research Council
Funding Amount
$830,952.00
Summary
This study will determine early childhood risk factors for psychosis-proneness in children aged 11 years, and emerging signs and symptoms of mental health disorders of these children, using population data from the NSW Child Development Study. Determining risk for psychosis as early as possible in the life course will enable the provision of preventative interventions to children at critical points in development.
The Efficacy Of N-acetyl Cysteine As An Adjunctive Treatment For First Episode Psychosis
Funder
National Health and Medical Research Council
Funding Amount
$2,143,069.00
Summary
First episode psychosis may foreshadow devastating, chronic illness. Psychosis follows a staged, progressive pathway. There is evidence to suggest illness progression can be diminished and perhaps even averted if appropriate treatments are given at the early stages of illness. This project will test if N-acetycysteine (NAC) administered to young people who have experienced a first episode of psychosis can help prevent this early psychotic experience from developing into a chronic disorder.
Improving Physical Health Outcomes For Young People With Psychotic Disorders
Funder
National Health and Medical Research Council
Funding Amount
$189,384.00
Summary
Enduring psychotic disorders are associated with a reduced life expectancy by 25 years, which is mainly due to cardiovascular disease. This project will produce a training package that will improve clinician’s skills and knowledge of screening and treatment for physical health risk factors in young people with psychosis. This project will result in the development of an intervention for reducing the prevalence of these cardiovascular risk factors known to contribute to this early mortality.
Acceptance And Commitment Therapy For Medication-resistant Psychosis: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$558,200.00
Summary
In spite of advances in medication, approximately one third of people with schizophrenia continue to experience distressing symptoms such as hearing voices and paranoia. Psychological 'talking treatments' are effective in helping people to cope with and be less distressed by these experiences. This study will be the first trial of a new psychological treatment, called Acceptance and Commitment Therapy, which may be more effective, briefer and more easily provided than existing approaches.